Hero Finding
At second-line in 2030, the asset of interest captures a majority of physician sample share, displacing the incumbent on safety and turnaround.
Across 71 hematologist-oncologists, the asset of interest is projected to grow from a minority position at second line in 2026 to a majority by 2030, while the first-mover share falls and the legacy product drifts further down the curve. The swing is driven by the asset's cleaner late-onset toxicity profile and a materially shorter manufacturing turnaround versus the incumbent.
Indexed product sample share at second line in 2030 · indexed to peak share = 100 · N=71 hematologist-oncologists · valuesReindexed: true
Key Findings
What the diligence surfaced.
Six signals shaped the investment team's view of the safety swing, the operational moat, and the long-term modality contest.
Efficacy is at parity, so safety and logistics carry the decision.
A strong majority of clinicians characterize the asset of interest and the first-mover as roughly comparable on overall response and progression-free survival. With efficacy at parity, a strong majority rate the asset's safety profile as preferable, citing a materially cleaner late-onset neurologic toxicity profile relative to the incumbent.
A materially shorter manufacturing turnaround is treated as a clinical attribute, not a convenience.
A strong majority rank manufacturing reliability as a primary decision driver, ahead of efficacy and payer policy. A turnaround that is roughly a third of the incumbent's unlocks treatment of time-sensitive patients who today rely on bridging therapy or progress while waiting.
By 2030 the asset of interest holds a majority of second-line sample share.
Second-line indexed product sample share for the asset moves from a minority position in 2026 to a clear majority in 2030, a steep directional gain. The first-mover trajectory bends down by a roughly equivalent magnitude. Third-line share also rises in the base case and accelerates further under a discount pricing scenario.
First-generation cellular therapy is being relegated to later lines or out of practice.
A sizable minority expect the legacy product to be relegated to third line or later, and a smaller cohort predict full market obsolescence. Across 2L through 5L, legacy share declines steadily through 2030 as competitive consolidation hardens around a high-efficacy, high-safety standard.
Treatment sequencing is shifting to switch target class, reinforcing pressure to use the best cellular therapy first.
A majority of clinicians prefer not to retreat with the same target class at relapse, citing antigen resistance. A majority name a different-target therapy as the default next step. The hardening of switch-target sequencing makes the first cellular therapy choice strategically heavier and rewards safety and durability.
Adoption velocity is gated by formulary committees and insurance authorization, not by clinical resistance.
A majority rate the physical act of switching from the first-mover to the asset as operationally easy. A majority cite hospital formulary approvals and insurance authorization cycles as the primary adoption constraint, creating a lag between clinical willingness and realized utilization.
The clinicians most familiar with the incumbent are the ones forecasting its decline.
The expected pattern would be that current incumbent users defend the product they know. The data runs the other way. Among the strong majority who report being very familiar with the first-mover's clinical data and the roughly half who run high-volume procedures at academic centers, the projected share trajectory for the asset of interest is steeper, not flatter. The same clinicians who treat the most patients in this disease describe the safety swing with the most specificity, articulate the manufacturing constraint most concretely, and project the earliest crossover. Familiarity with the incumbent accelerates rather than blunts adoption of the asset, once safety and turnaround are validated in real-world settings.
Since efficacy is more or less equivalent, the safety and operational advantages will make the asset of interest the more practical and broadly usable option in real-world care. The shorter turnaround and the cleaner late-onset toxicity profile are what make this decisive in my practice.
Hematologist-Oncologist · Academic Medical Center
Study Design
N=71US hematologist-oncologists
All with direct cellular therapy experience in the indication
Structured in-depth interviews
The sample was designed to reflect where cellular therapy volume actually sits today: heavy academic concentration, high procedure volume, and balanced exposure to commercial and clinical-stage assets in the class. Familiarity with both incumbent and asset-of-interest clinical data was screened for at recruit.
Sample by segment
Mix
What the guide covered
- Comparative clinical trial interpretation: efficacy, safety, manufacturing turnaround
- Clinical differentiators and decision-making hierarchy across products in the class
- Product-specific assessment, including future role of the first-generation incumbent
- Treatment selection and adoption drivers by disease stage
- Conditions for cellular therapy adoption across lines of therapy
- Switching ease, formulary, and reimbursement gating
- Line-of-therapy product sample share forecasts across the 2026 to 2030 window
- Long-term modality contest with adjacent biologic approaches and combinations
Who qualified
- Attending hematologist-oncologists in active US clinical practice
- Direct experience administering cellular therapy in the relevant indication in the past 12 months
- Familiar with clinical trial data for the asset of interest and the incumbent
- Mix of academic medical centers, large community cancer centers, and private practice
- Geographically diverse representation across US regions
Crosstab · Line-of-Therapy Share
Indexed product sample share trajectory by line of therapy.
Physician-projected directional share of patients receiving each cellular therapy as their first product, by line of therapy and forecast year. Values reindexed to the asset's 2030 second-line peak = 100. Highlighted row = the asset's second-line trajectory, the steepest swing in the dataset.
| 2026 | 2028 | 2030 | Trajectory | |
|---|---|---|---|---|
| Asset of interest · 2L | 55 | 81 | 100 | Steep gain |
| First-mover · 2L | 68 | 51 | 40 | Steep decline |
| Asset of interest · 3L | 60 | 85 | 85 | Strong gain |
| Asset of interest · 4L | 66 | 79 | 83 | Moderate gain |
| Asset of interest · 5L | 66 | 74 | 74 | Mild gain |
| Legacy product · all lines | 36 | 30 | 23 | Decline |
N=71 hematologist-oncologists · valuesReindexed: true · Indexed · blinded values · Earlier lines show the largest swing · Pricing scenario sensitivity is largest at third line
Voice of Customer
What hematologist-oncologists actually said.
Verbatim excerpts from the full interview sample, selected to span academic and community practice, trial investigators and non-investigators, and high and low procedure volume.
“My key factor is that the asset of interest shows a materially cleaner late-onset neurologic toxicity profile. That is what is most decisive to me. The gap relative to the incumbent shapes how I counsel patients.”
“It is mind-boggling to me that the manufacturing turnaround is so much shorter, with very tight variability. This would absolutely be my go-to product for time-sensitive patients in this disease.”
“I would not retreat with the same target class at relapse. I would likely use something with a different mechanism of action. That makes the first product choice carry more weight.”
“In older and frailer patients, where I am worried about long-term neurologic disability, I would go this route. The cleaner toxicity profile and the shorter turnaround are what make it usable for patients I currently struggle to treat with the incumbent.”
“The important issue with switching from the incumbent will be reimbursement by insurance. Otherwise, there is no other barrier. We would have to meet with the P and T committee and develop strategies to address some issues, just as with adding any new medication.”
Implications · what the evidence supports
Three readings from the diligence.
The research grounded the investment team's view of where commercial value will be created and where it could be eroded across the 2026 to 2030 window.
Second-line and third-line capture is the window before adjacent biologic approaches crowd later lines.
Earlier lines are where the asset's safety and turnaround advantages compound. Second-line sample share grows steeply through 2030 and third-line gains as well, while the long-term role of adjacent biologic combinations hardens at 4L plus. The investment thesis that fits the data weights earlier-line uptake heavily and discounts later-line contribution accordingly.
Formulary and insurance authorization are the primary go-to-market work.
Clinical willingness is high, with a majority rating the switch as operationally easy. The binding constraint is administrative: a majority cite formulary and insurance authorization as the primary adoption gate. The data puts P and T committee enablement and payer access at parity with clinical evidence dissemination.
Pricing scenarios and manufacturing capacity are the forecast's two sensitivities.
Third-line share is the most pricing-sensitive segment, with directional swings as large as the second-line gain itself when discounting is modeled. Manufacturing capacity is the second sensitivity, since slot availability gates the time-sensitive patient segment that anchors the safety thesis.
Signals the data flagged
- Asset of interest second-line sample share at or above the projected directional majority by 2030 in tracking studies
- Manufacturing turnaround held at the asset's launch target with tight variability across launch markets
- Hospital formulary inclusion at a strong majority of academic medical centers within 18 months of approval
- Real-world late-onset neurologic toxicity rates confirmed at trial-data levels in post-marketing data
Risks the data surfaced
| Adjacent biologic encroachment in 4L+ and frail populations | Med |
| Manufacturing capacity constraints throttle time-sensitive segment | High |
| Pricing pressure reshapes 3L share materially | High |
| Formulary and payer authorization lag delays clinical willingness | Med |
| Real-world safety profile diverges from trial data | Low |
| Switch-target sequencing reduces same-class retreatment volume | Low |